Tyvaso DPI™ production is underway at MannKind Corporation (Nasdaq: MNKD) in Danbury, Conn. On May 24, 2022, MannKind celebrated that the U.S. Food and Drug Administration (FDA) has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder. Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s innovative Technosphere® inhalation technology. MannKind and United Therapeutics (Nasdaq: UTHR) entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development and commercialization of Tyvaso DPI.
Tyvaso DPI™ production is underway at MannKind Corporation (Nasdaq: MNKD) in Danbury, Conn. On May 24, 2022, MannKind celebrated that the U.S. Food and Drug Administration (FDA) has approved United Therapeutics’ Tyvaso DPI™ (treprostinil) inhalation powder. Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s innovative Technosphere® inhalation technology. MannKind and United Therapeutics (Nasdaq: UTHR) entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development and commercialization of Tyvaso DPI.